Sensus Healthcare (NASDAQ: SRTS) reported second-quarter 2026 revenue of $2.3 million, down significantly from $7.3 million in the same period last year. The results missed analyst expectations, with quarterly sales of $2.290 million falling short of the $4.601 million consensus estimate by 50.23%. The decline was primarily attributed to fewer units sold and the delayed recognition of revenue for eight units due to unresolved third-party financing approvals, which management expects to recognize in the third quarter of 2026.

The company recorded a net loss of $8.7 million ($0.53 per share) for the quarter, widening from a net loss of $1.0 million ($0.06 per share) in Q2 2025. This deterioration included a $5.7 million valuation allowance against net deferred tax assets. The reported EPS of $(0.53) missed the analyst consensus estimate of $(0.13) by 341.67%. Despite the top-line contraction, operating expenses decreased year-over-year as the company reduced compensation, marketing, and research costs.

Financial Performance

Revenue fell approximately $5 million year-over-year, driven by a drop in unit sales from 19 units in Q2 2025 to 11 units in Q2 2026. Cost of sales declined proportionally to $1.5 million from $4.4 million in the prior-year period.

Gross profit contracted to $0.8 million from $2.9 million, with gross margin slipping to 34.8% from 39.7%. Management cited product mix shifts, including a higher proportion of international shipments with lower average selling prices, and costs associated with new system placements under the Fair Deal Agreement program as primary drivers for the margin compression.

Operating expenses totaled $4.0 million, down from $4.9 million in Q2 2025. General and administrative expenses fell to $1.8 million from $2.0 million, aided by lower compensation costs. Selling and marketing expenses dropped to $1.1 million from $1.4 million, reflecting reduced trade show and clinical research costs. Research and development expenses also declined to $1.1 million from $1.5 million due to lower product development costs and reduced headcount.

What the Numbers Show

The divergence between operational cost discipline and widening losses highlights the impact of non-operational items on profitability. While operating expenses decreased by nearly $1 million year-over-year, the net loss expanded by $7.7 million. This discrepancy is largely driven by a $5.7 million valuation allowance against net deferred tax assets included in Q2 2026 results, alongside a drop in other income from $2.2 million to $0.1 million. Excluding these non-recurring and interest-related factors, the core operational loss widened modestly, indicating that while cost-cutting measures are effective, they have not yet offset the significant revenue shortfall caused by the delayed unit recognitions.

Balance Sheet and Outlook

Cash and cash equivalents stood at $15.2 million as of June 30, 2026, down from $18.3 million at the end of March 2026. The company had no outstanding borrowings under its revolving line of credit. Inventory increased to $18.4 million from $16.5 million in the previous quarter, providing capacity to support future equipment sales and placements.

Management emphasized strong commercial momentum, citing a growing pipeline and increased interest from larger healthcare organizations. International expansion efforts are underway in Asia Pacific, particularly in Australia and New Zealand, markets identified for their high skin cancer prevalence. The company anticipates stronger performance in the second half of 2026, focusing on converting pipeline opportunities into revenue and expanding adoption of its SRT technology through new CPT codes and improved reimbursement clarity.

Key commercial developments include:

• CMS Reimbursement: The Centers for Medicare & Medicaid Services (CMS) proposed a 26% increase in the hospital-based SRT delivery code. If finalized, this would improve provider economics and support expanded adoption across hospital settings.
• Digital Engagement: Active website users increased 153% year-over-year, signaling growing physician engagement and inbound customer inquiries.
• Pipeline Strength: Sales pipeline strengthened following CPT code implementation, with broadened relationships with larger physician groups and increased utilization under the Fair Deal Agreement program.

Sensus Healthcare, Inc. (NASDAQ: SRTS) will report its financial results for the second quarter of 2026 on Thursday, August 13, 2026. The medical device company, which specializes in non-invasive treatments for oncological and non-oncological skin conditions, will also hold a business update conference call beginning at 4:30 pm Eastern time. Investors are advised to monitor the release for key metrics regarding revenue, net profit, and operational progress in its superficial radiotherapy segment.

The conference call is designed to review the quarterly results, provide a broader business update, and answer questions from analysts and investors. Participants are encouraged to pre-register using the provided link to receive a unique dial-in number, which allows them to bypass the live operator. Pre-registration can be completed at any time, including up to and after the call start time.

For those unable to pre-register, access to the conference call is available by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Callers should ask the operator to connect them to the Sensus Healthcare conference call. This ensures seamless access for all stakeholders interested in the company’s latest financial performance.

The call will also be webcast live and can be accessed through the company’s website or the dedicated event link. The live stream will be archived in the Investor Relations section of www.sensushealthcare.com for later viewing. This provides flexibility for global investors who may not be able to attend the live session due to time zone differences.

Sensus Healthcare operates as a global pioneer in developing non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company offers healthcare providers a patient-centric treatment platform. The firm emphasizes safety, precision, and adaptability across various clinical settings in radiation oncology.

Investor relations inquiries can be directed to Leigh Salvo at New Street Investor Relations via email at leigh@newstreetir.com . As the results date approaches, market participants will likely focus on any updates regarding product adoption rates, regulatory developments, or strategic partnerships that could influence future growth trajectories.